Price History

Hover for the daily close. The dotted line marks the period open.

Compare VRXA with… →

VRXA Key Statistics

As of Sep 4, 2026

Trading

Open: $1.57
Previous Close: $1.53
Day's Range: 1.53–1.97
52-Week Range: 1.27–27.36
Volume: 3.58M

Valuation

Market Cap: $248.88M
P/E Ratio: unprofitable
EPS (ttm): −0.58

Financials (FY)

Revenue (FY): $23.43K
Net Income (FY): −$66.61M
Profit margin: 0.00%
Shares Outstanding: 141.41M
1-Year Return: −83.11%

Dividend and dates

Avg Volume: 555.73K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VRXA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+0.50%+6.49%−83.51%

2024*20252026*

Year	Return
2026 (partial year)	−83.51%
2025	+6.49%
2024 (partial year)	+0.50%

As of September 4, 2026.

VRXA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$23.43K	−$66.61M	−284359.2%
2024	$0.00	−$28.13M	—
2023	$0.00	−$16.54M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$23.43K	$15.46K	−$66.22M	−$66.61M	−284359.2%
2024	$0.00	$0.00	−$28.92M	−$28.13M	—
2023	$0.00	—	−$16.66M	−$16.54M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VRXA Valuation vs Biotechnology Median

Median of 654 stocks

Metric	VRXA	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 654 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Veraxa Biotech AG (VRXA) is capitalised at $248.88M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for VRXA is $1.76, dated September 4, 2026. That is +$0.23 (+15.03%) against the previous close. The 52-week range on file runs from $1.27 to $27.36. The latest close sits 38.58% above that 52-week low.

Financial Health

In fiscal 2025, Veraxa Biotech AG reported revenue of $23.43K. The same year closed with a net loss of $66.61M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.58.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $23.43K in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is −83.11%. The stored price history starts on September 30, 2024, and the total return since then is −82.35%. Annualized volatility over the trailing 1 year is 132.08%.

Growth & Income

No dividend is on file for VRXA.

The record holds one complete calendar year, 2025, which returned +6.49%. So far in 2026 the price is −83.51%.

Peer Comparison

Veraxa Biotech AG (VRXA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Veraxa Biotech AG	VRXA	$248.88M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	31.8
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	39.4

The Biotechnology industry average P/E ratio is 12.9x. Veraxa Biotech AG has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Veraxa Biotech AG

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.

Visit website →

Veraxa Biotech AG (VRXA) Stock Analysis